Supernus Pharmaceuticals Inc (SUPN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Supernus Pharmaceuticals Inc (SUPN) has a cash flow conversion efficiency ratio of 0.062x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($66.52 Million) by net assets ($1.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Supernus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Supernus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SUPN total liabilities for a breakdown of total debt and financial obligations.
Supernus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Supernus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SpareBank 1 Østlandet
OL:SPOL
|
-0.018x |
|
XL Axiata Tbk PT
JK:EXCL
|
0.144x |
|
CES Energy Solutions Corp
TO:CEU
|
0.082x |
|
Aura Minerals Inc
TO:ORA
|
0.571x |
|
Centrais Elétricas Brasileiras S.A. - Eletrobrás
NYSE:EBR-B
|
0.039x |
|
Central Depository Services (India) Limited
NSE:CDSL
|
0.188x |
|
Sivers IMA Holding AB
ST:SIVE
|
-0.016x |
|
Robotis Co.Ltd
KQ:108490
|
0.003x |
Annual Cash Flow Conversion Efficiency for Supernus Pharmaceuticals Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Supernus Pharmaceuticals Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see SUPN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.06 Billion | $47.33 Million | 0.045x | -73.15% |
| 2024-12-31 | $1.04 Billion | $171.95 Million | 0.166x | +37.72% |
| 2023-12-31 | $921.52 Million | $111.08 Million | 0.121x | -8.56% |
| 2022-12-31 | $886.20 Million | $116.83 Million | 0.132x | -15.40% |
| 2021-12-31 | $815.85 Million | $127.13 Million | 0.156x | -16.14% |
| 2020-12-31 | $744.86 Million | $138.40 Million | 0.186x | -22.70% |
| 2019-12-31 | $595.43 Million | $143.13 Million | 0.240x | -15.57% |
| 2018-12-31 | $453.02 Million | $128.99 Million | 0.285x | -33.57% |
| 2017-12-31 | $267.48 Million | $114.64 Million | 0.429x | +23.01% |
| 2016-12-31 | $191.75 Million | $66.81 Million | 0.348x | +28.94% |
| 2015-12-31 | $118.88 Million | $32.12 Million | 0.270x | +149.34% |
| 2014-12-31 | $71.35 Million | $7.73 Million | 0.108x | +106.26% |
| 2013-12-31 | $33.46 Million | $-57.95 Million | -1.732x | -111.22% |
| 2012-12-31 | $57.57 Million | $-47.20 Million | -0.820x | +78.60% |
| 2011-12-31 | $9.44 Million | $-36.19 Million | -3.832x | -621.85% |
| 2010-12-31 | $-44.32 Million | $-32.54 Million | 0.734x | +271.61% |
| 2009-12-31 | $-6.16 Million | $2.63 Million | -0.428x | -109.74% |
| 2008-12-31 | $-6.75 Million | $-29.65 Million | 4.395x | -- |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more